Empowered Funds LLC Buys 11,149 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Empowered Funds LLC grew its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 5.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 229,485 shares of the company’s stock after acquiring an additional 11,149 shares during the period. Empowered Funds LLC owned 0.50% of Pacira BioSciences worth $4,323,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of PCRX. Pacer Advisors Inc. raised its position in Pacira BioSciences by 129.4% in the 3rd quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company’s stock worth $74,681,000 after purchasing an additional 2,799,434 shares during the last quarter. State Street Corp increased its stake in shares of Pacira BioSciences by 5.8% in the 3rd quarter. State Street Corp now owns 2,014,012 shares of the company’s stock valued at $30,311,000 after buying an additional 110,162 shares during the period. Assenagon Asset Management S.A. raised its position in shares of Pacira BioSciences by 314.4% during the third quarter. Assenagon Asset Management S.A. now owns 553,114 shares of the company’s stock worth $8,324,000 after acquiring an additional 419,656 shares during the last quarter. Impax Asset Management Group plc lifted its stake in shares of Pacira BioSciences by 81.0% during the third quarter. Impax Asset Management Group plc now owns 470,603 shares of the company’s stock valued at $7,083,000 after acquiring an additional 210,576 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Pacira BioSciences by 4.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 431,897 shares of the company’s stock valued at $6,500,000 after acquiring an additional 16,819 shares during the last quarter. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Pacira BioSciences Stock Up 4.4 %

NASDAQ:PCRX opened at $27.25 on Wednesday. Pacira BioSciences, Inc. has a 1 year low of $11.16 and a 1 year high of $31.67. The stock has a 50-day moving average price of $21.35 and a two-hundred day moving average price of $17.95. The stock has a market cap of $1.26 billion, a price-to-earnings ratio of -13.42 and a beta of 0.80. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Royal Bank of Canada restated a “sector perform” rating and set a $18.00 target price on shares of Pacira BioSciences in a research report on Tuesday, January 14th. HC Wainwright reaffirmed a “buy” rating and issued a $39.00 price objective on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Truist Financial raised shares of Pacira BioSciences from a “sell” rating to a “hold” rating and lifted their target price for the stock from $8.00 to $25.00 in a report on Thursday, January 30th. Needham & Company LLC increased their price target on Pacira BioSciences from $22.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, January 13th. Finally, Barclays decreased their price objective on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 12th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $22.78.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.